FDA updates certain COVID-19 drug compounding guidance
The Food and Drug Administration yesterday updated two guidances for the temporary compounding of certain drugs used to treat COVID-19 patients.
The for temporary compounding of certain drugs for outsourcing facilities now includes information to help hospitals determine which facilities are covered by the policy, and clarifies policies for testing both container-closures and product stability. It also says FDA will not take action against outsourcing facilities for filling drug orders for copies of FDA-approved products.
In addition, FDA updated for temporary compounding of certain drugs by pharmacy compounders to include reporting to FDA any adverse events associated with drugs they compounded.
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…